Ochre Bio and GSK Team Up to Explore the Drivers of Liver Disease
Shots:
- Ochre Bio & GSK have entered into ~$37.5M multi-year data license agreement covering both co-exclusive & non-exclusive data rights
- GSK gains access to Ochre Bio’s computational biology, cellular & perfused human organ platforms plus non-exclusive access to the collection of historical liver data for creating human liver datasets. Data from single-cell sequencing of perfused human livers & large-scale gene perturbation in human liver cells are included
- The companies intend to understand liver biology to develop therapies targeting liver disease by utilizing the generated insights & forming AI models to perform specific experiments aiding in target choice, complementing GSK’s disease area focus in hepatology
Ref: Businesswire | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
